Скачать с ютуб Geoff Chong, MD, Shares Data on Novel Bispecific Antibody in Follicular Lymphoma в хорошем качестве

Geoff Chong, MD, Shares Data on Novel Bispecific Antibody in Follicular Lymphoma

Dr. Chong, an Associate Professor at the Olivia Newton-John Cancer Centre, discusses his research presented at the American Association for Cancer Research Annual Meeting 2024. The ELM-2 trial studied odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed or refractory follicular lymphoma. The objective response rate was 80.5%, the complete response rate was 73.4%, and the median progression-free survival was 20.7 months. Dr. Chong described the safety as “generally manageable.” About half (56.7%) of patients experienced grade 1 cytokine release syndrome (CRS), 45% had grade 2 CRS, and 10% had grade 3 CRS. Infection occurred in about 80% of patients. “There are high response and complete response rates in the relapsed or refractory population,” Dr. Chong said. “We’re certainly on to a good treatment for the future, and this trial provides a good setting for further investigation of odronextamab.”